Jerini AG has entered into a strategic discovery and development collaboration with Alcon Research, Ltd. to generate novel drugs for ophthalmology.

As part of the multi-year, multi-target alliance, the parties will employ Jerini's proprietary Peptides-To-Drugs (P2D) discovery platform, including SPOT, pepSPOT and pepMED, along with other technologies, to generate peptidomimetic (PM) and small-molecule (SM) drug candidates and validate their utility for treatment of eye diseases.

Jerini will receive up-front and license fees as well as personnel funding (FTE), milestone payments and worldwide royalties on commercial sales of products resulting from the collaboration. Financial terms were not disclosed, according to the release.

"We are delighted to gain Alcon, the global leader in ophthalmology, as a partner to discover and develop innovative therapies for eye diseases. This is our third significant P2D partnership within the past twelve months," says Adi Hoess, chief commercial officer of Jerini.

Jerini AG has built a pipeline of several preclinical and clinical projects with its proprietary Peptides-To-Drugs (P2D) discovery platform.